Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis

被引：0
|
作者：
Juanzhi Fang
Stephanie Korrer
Jonathan C. Johnson
Mark A. Cheadle
Roshani Shah
Matias L. Ferraris
Cristina Lopez-Lopez
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Optum,undefined
[3] Novartis Pharma AG,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Acute; Comorbidity; Erenumab; Migraine; Observational; Preventive; Real world; Retrospective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2921 / 2934
页数：13
相关论文
共 50 条
  • [21] Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience
    Mahovic, Darija
    Bracic, Matea
    Jakus, Lukrecija
    Cvetkovic, Vlasta Vukovic
    Krpan, Marina
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 214
  • [22] Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
    Kanaan, Saad
    Hettie, Gabrielle
    Loder, Elizabeth
    Burch, Rebecca
    CEPHALALGIA, 2020, 40 (13) : 1511 - 1522
  • [23] Real-world effectiveness data of erenumab-treated migraine patients in Switzerland: The SQUARE study
    Schafer, E.
    Arzt, M.
    Meyer, I.
    Gantenbein, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 235 - 236
  • [24] Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
    Armin Scheffler
    Olga Messel
    Sebastian Wurthmann
    Michael Nsaka
    Christoph Kleinschnitz
    Martin Glas
    Steffen Naegel
    Dagny Holle
    The Journal of Headache and Pain, 2020, 21
  • [25] Real-world effectiveness data of erenumab-treated migraine patients in Switzerland: The SQUARE study
    Schafer, E.
    Arzt, M.
    Meyer, I.
    Gantenbein, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [26] Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
    Anna P. Andreou
    Matteo Fuccaro
    Bethany Hill
    Madeleine Murphy
    Valeria Caponnetto
    Rachael Kilner
    Giorgio Lambru
    The Journal of Headache and Pain, 2022, 23
  • [27] Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
    Scheffler, Armin
    Messel, Olga
    Wurthmann, Sebastian
    Nsaka, Michael
    Kleinschnitz, Christoph
    Glas, Martin
    Naegel, Steffen
    Holle, Dagny
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [28] Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
    Andreou, Anna P.
    Fuccaro, Matteo
    Hill, Bethany
    Murphy, Madeleine
    Caponnetto, Valeria
    Kilner, Rachael
    Lambru, Giorgio
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [29] Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey
    Pathak, Purnima
    Yue, Leiyu
    Gupta, Shaloo
    Fang, Juanzhi
    Cheadle, M. Andy
    Tiwari, Santosh
    Ferraris, Matias
    Joshi, Parth
    Thompson, Jeffrey
    Shah, Roshani
    Vo, Pamela
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (12) : 1585 - 1591
  • [30] Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
    Fernandez-Bravo-Rodrigo, Jaime
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Flor-Garcia, Amparo
    Barreda-Hernandez, Dolores
    Pascual-Morena, Carlos
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 976
12345